UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Journal of clinical oncology, 2022-03, Vol.40 (7), p.762-771

2022

Link zum Volltext

Verfügbarkeit prüfen

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

Journal of clinical oncology, 2014-04, Vol.32 (10), p.1031-1039

2014

Link zum Volltext

Verfügbarkeit prüfen

Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.675-675

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world experience in advanced NSCLC using FDA approved NGS CDx

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14602-e14602

2019

Link zum Volltext

Verfügbarkeit prüfen

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Journal of clinical oncology, 2023-04, Vol.41 (10), p.1849-1863

2023

Link zum Volltext

Verfügbarkeit prüfen

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK21100delC Carriers

Journal of clinical oncology, 2016-08, Vol.34 (23), p.2750-2760

2016

Link zum Volltext

Verfügbarkeit prüfen

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1116-1128

2023

Link zum Volltext

Verfügbarkeit prüfen

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9155-TPS9155

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS814-TPS814

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3089-3089

2021

Link zum Volltext

Verfügbarkeit prüfen

Genomic characterization of cholangiocarcinoma with autoimmune etiologies

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.531-531

2024

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy

Journal of clinical oncology, 2022-07, Vol.40 (21), p.JCO2101536-2374

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study

Journal of clinical oncology, 2023-04, Vol.41 (10), p.1921-1932

2023

Link zum Volltext

Verfügbarkeit prüfen

Frailty and pre-frailty associated with physical functional performance and quality of life in breast cancer and bone marrow transplant survivors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.12064-12064

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11560-11560

2023

Link zum Volltext

Verfügbarkeit prüfen

PORTO-001 study: Changes in the oral microbiome and matrix metalloproteinases in patients with oropharyngeal squamous cell carcinoma undergoing definitive chemoradiotherapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18034-e18034

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of serum miR-371a-3p assay performance by digital droplet PCR and reverse transcriptase quantitative PCR in patients with malignant germ cell tumor

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.426-426

2023

Link zum Volltext

Verfügbarkeit prüfen

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.237-237

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS758-TPS758

2023

Link zum Volltext

Verfügbarkeit prüfen

Overall and progression-free survival in young breast cancer patients with low muscle mass and density

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.12052-12052

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2515-2515

2021

Link zum Volltext

Verfügbarkeit prüfen

Telemedicine use and satisfaction amongst radiation oncologists during the COVID-19 pandemic: Evaluation of current trends and future opportunities

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13503-e13503

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2630-2630

2021

Link zum Volltext

Verfügbarkeit prüfen

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS185-TPS185

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 103

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(103)

Sprache

Englisch
(103)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy

Real-world experience in advanced NSCLC using FDA approved NGS CDx

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK21100delC Carriers

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC)

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis

Genomic characterization of cholangiocarcinoma with autoimmune etiologies

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study

Frailty and pre-frailty associated with physical functional performance and quality of life in breast cancer and bone marrow transplant survivors

Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials

PORTO-001 study: Changes in the oral microbiome and matrix metalloproteinases in patients with oropharyngeal squamous cell carcinoma undergoing definitive chemoradiotherapy

Comparison of serum miR-371a-3p assay performance by digital droplet PCR and reverse transcriptase quantitative PCR in patients with malignant germ cell tumor

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer

A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer

Overall and progression-free survival in young breast cancer patients with low muscle mass and density

Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study

Telemedicine use and satisfaction amongst radiation oncologists during the COVID-19 pandemic: Evaluation of current trends and future opportunities

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Aktive Filter

Suchergebnisse filtern